There are currently 168 active clinical trials seeking participants for Lung Cancer research studies. The states with the highest number of trials for Autism participants are Ohio, California, Illinois and Michigan.
Increasing Equity in Lung Cancer Screening
NCT06360822
Recruiting
The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key stakeholders; 2) pilot test the ED-LCS intervention evaluating the intervention efficacy, acceptability, and feasibility; and 3) provide an in-depth description of stakeholders' experiences with the ED-LCS intervention for future refinement.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/08/2024
Locations: Eskenazi Health, Indianapolis, Indiana
Conditions: Lung Cancer
Register for Updates
A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT06051695
Recruiting
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express MSLN and have lost HLA-A*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose of A2B694 that is safe for patients Phase 2: Does the recommended dos... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/07/2024
Locations: UCSD Moores Cancer Center, La Jolla, California +8 locations
Conditions: Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Register for Updates
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
NCT01441089
Recruiting
Background: - Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: - To obtain a blood or cheek swab sample to study genetic differences that may affect cancer treatment. Eligibility: - Individuals with cancer who are being treated at the National Cancer Institute. De... Read More
Gender:
All
Ages:
3 years and above
Trial Updated:
04/06/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
Register for Updates
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
NCT04367311
Recruiting
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy. However, relapse rates remain high and are primarily due to distant, metastatic disease. Previous meta-analysis evaluating the use of neo-adjuvant chemotherapy and adjuvant chemotherapy demonstrate a similar impact on improved disease free survival (DFS) and overall survival (OS). The role of checkpoint inhibitors has been proven to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +9 locations
Conditions: Lung Cancer, NSCLC
Register for Updates
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT04038619
Recruiting
This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Colitis, Diarrhea, Malignant Genitourinary System Neoplasm, Melanoma, Lung Cancer, Ovarian Cancer, Uterine Cancer, Breast Cancer, Cervical Cancer
Register for Updates
Rural Lung and Head and Neck Cancer Intervention
NCT04916990
Recruiting
This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment completion for Lung Cancer and Head and Neck Cancer patients.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/03/2024
Locations: University of Colorado Hospital, Aurora, Colorado +10 locations
Conditions: Lung Cancer, Head and Neck Cancer
Register for Updates
The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale
NCT06338592
Recruiting
Early lung cancer screening (LCS) through low-dose computed tomography (LDCT) is crucial but underused due to various barriers, including incomplete or inaccurate patient smoking data in the electronic health record and limited time for shared decision-making. The objective of this trial is to investigate a patient-centered intervention, MyLungHealth, delivered through the patient portal. The intervention is designed to improve LCS rates through increased identification of eligible patients and... Read More
Gender:
All
Ages:
Between 50 years and 79 years
Trial Updated:
04/03/2024
Locations: NYU Langone Health, New York, New York +1 locations
Conditions: Lung Cancer, Lung Neoplasms/Diagnosis
Register for Updates
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
NCT06125197
Recruiting
This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California +1 locations
Conditions: Lung Cancer
Register for Updates
Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
NCT05845671
Recruiting
Although non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK), c-ros oncogene 1(ROS1), and ret proto-oncogene (RET) gene fusions initially respond well to tyrosine kinase inhibitor (TKI) therapies, acquired resistance is inevitable. In many of these cases, increased activation of the erythroblastic leukemia viral oncogene homologue (ERBB) or cMet pathways appears to be a bypass signaling mechanism that allows these cancer cells to circumvent the selective pressure fr... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/02/2024
Locations: Colorado Research Center, Aurora, Colorado +3 locations
Conditions: Lung Cancer, Non Small Cell Lung Cancer
Register for Updates
Tempus Priority Study: A Pan-tumor Observational Study
NCT05179824
Recruiting
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.
Gender:
All
Ages:
All
Trial Updated:
04/02/2024
Locations: Providence Medical Foundation, Napa, California +11 locations
Conditions: Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer
Register for Updates
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
NCT05401110
Recruiting
The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objec... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Cedars-Sinai Cancer at Beverly Hills (THO), Beverly Hills, California +4 locations
Conditions: Non Small Cell Lung Cancer, Lung Cancer
Register for Updates
Enhancing Lung Cancer Screening Through Human-Centered Intervention
NCT06351085
Recruiting
The purpose of this study is to further understand the factors involved in increasing lung cancer screening.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/01/2024
Locations: University of California, Davis, Sacramento, California
Conditions: Lung Cancer
Register for Updates